{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:17:11Z","timestamp":1790079431468,"version":"4.0.1"},"reference-count":50,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s336285","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T09:30:06Z","timestamp":1656495006000},"page":"2055-2066","source":"Crossref","is-referenced-by-count":22,"title":["Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Bradley S","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin CJ","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1210\/jcem-18-8-901","volume":"18","author":"Raben","year":"1958","journal-title":"J Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/adc.54.8.609","volume":"54","author":"Lippe","year":"1979","journal-title":"Arch Dis Child"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ghir.2015.12.002","volume":"26","author":"De Pedro","year":"2016","journal-title":"Growth Horm Igf Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1542\/peds.102.S3.512","volume":"102","author":"August","year":"1998","journal-title":"Pediatrics"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.17458\/per.vol16.2018.25yearsghdata","volume":"16","author":"Bell","year":"2018","journal-title":"Pediatr Endocrinol Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/jc.2018-01189","volume":"104","author":"Child","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000508190","volume":"93","author":"Pfaffle","year":"2020","journal-title":"Horm Res Paediatr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1210\/jc.2005-2284","volume":"91","author":"Reiter","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ghir.2015.08.006","volume":"25","author":"Ross","year":"2015","journal-title":"Growth Horm Igf Res"},{"key":"ref10","unstructured":"Miller BS, Rose SR, Ross JL, et al. Growth hormone dosage associated with change in height standard deviation score over 4 years of treatment by age in pediatric patients with Isolated Growth Hormone Deficiency (IGHD): results from the ANSWER program. Pediatric Academic Societies\u2019 Meeting; 2015; San Diego, CA."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/cen.13030","volume":"84","author":"Auer","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fendo.2019.00416","volume":"10","author":"Mancini","year":"2019","journal-title":"Front Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1210\/clinem\/dgz149","volume":"105","author":"Miller","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1530\/EJE-16-0748","volume":"176","author":"Strasburger","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.1279","volume":"4","author":"Deal","year":"2020","journal-title":"J Endocr Soc"},{"key":"ref16","unstructured":"Pfizer. OPKO and pfizer announce positive Phase 3 top-line results for somatrogon, an investigational long-acting human growth hormone to treat children with growth hormone deficiency; 2019. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/opko_and_pfizer_announce_positive_phase_3_top_line_results_for_somatrogon_an_investigational_long_acting_human_growth_hormone_to_treat_children_with_growth_hormone_deficiency. Accessed February 24, 2022."},{"key":"ref17","unstructured":"Pfizer. Pfizer and OPKO\u2019s once-weekly NGENLA\u2122 (somatrogon) injection receives marketing authorization in European Union for treatment of pediatric growth hormone deficiency; 2022. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-opkos-once-weekly-ngenlatm-somatrogon-injection. Accessed February 26, 2022."},{"key":"ref18","unstructured":"Park B. FDA denies approval of long-acting pediatric growth hormone therapy; 2021. Available from: https:\/\/www.empr.com\/home\/news\/drugs-in-The-pipeline\/fda-denies-approval-of-long-acting-pediatric-growth-hormone-therapy\/. Accessed February 24, 2022."},{"key":"ref19","unstructured":"ClinicalTrials.gov. A research study in children born small and who stayed small. treatment is somapacitan once a week compared to Norditropin\u00ae once a day; 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03878446. Accessed February 24, 2022."},{"key":"ref20","unstructured":"ClinicalTrials.gov. A research study in children with a low level of hormone to grow. treatment is somapacitan once a week compared to Norditropin\u00ae once a day (REAL4); 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03811535. Accessed February 24, 2022."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1210\/jc.2016-3776","volume":"102","author":"Chatelain","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ghir.2017.12.002","volume":"39","author":"Gilfoyle","year":"2018","journal-title":"Growth Horm Igf Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1530\/EC-17-0007","volume":"6","author":"Hoybye","year":"2017","journal-title":"Endocr Connect"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1210\/clinem\/dgab529","volume":"106","author":"Thornton","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"bvab168","DOI":"10.1210\/jendso\/bvab168","volume":"6","author":"Lin","year":"2022","journal-title":"J Endocr Soc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e2367","DOI":"10.1210\/clinem\/dgab016","volume":"106","author":"Bidlingmaier","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"ref27","unstructured":"ClinicalTrials.gov. A safety, tolerability and efficacy study of TransCon hGH in children with growth hormone deficiency; 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03305016. Accessed February 24, 2022."},{"key":"ref28","unstructured":"ClinicalTrials.gov. A long-term trial investigating safety and efficacy of TransCon hGH in children with growth hormone deficiency who have completed a prior TransCon hGH clinical trial (enliGHten); 2017. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03344458. Accessed February 24, 2022."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"01","DOI":"10.1210\/clinem\/dgz310","volume":"105","author":"Savendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaa046.963","volume":"4","author":"Maniatis","year":"2020","journal-title":"J Endocr Soc"},{"key":"ref31","first-page":"1","volume":"94","author":"Maniatis","year":"2021","journal-title":"Horm Res Paediatr"},{"key":"ref32","unstructured":"ClinicalTrials.gov. A trial to compare the efficacy and safety of once-weekly lonapegsomatropin with placebo and a daily somatropin product in adults with growth hormone deficiency (foresiGHt); 2020. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04615273. Accessed February 24, 2022."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"A676","DOI":"10.1210\/jendso\/bvab048.1378","volume":"5","author":"Maniatis","year":"2021","journal-title":"J Endocr Soc"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Thornton P, Hofman P, Maniatis AK, et al. TransCon growth hormone in the treatment of pediatric growth hormone deficiency results of the Phase 3 HeiGHt trial; 2019. https:\/\/ascendispharma.com\/wp-content\/uploads\/ENDO-2019-heiGHt-Trial-Presentation.pdf. Accessed July 8, 2019.","DOI":"10.1210\/js.2019-OR17-4"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-15-0873","volume":"174","author":"Allen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-16-0111","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000080760","volume":"62","author":"Park","year":"2004","journal-title":"Horm Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1210\/jc.2007-0204","volume":"92","author":"Cohen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"ref39","unstructured":"Ascendis. SKYTROFA\u2122 (lonapegsomatropin-tcgd) for injection, for subcutaneous use; 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761177lbl.pdf. Accessed February 12, 2022."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Walsh K, Campbell D, Permuy J, et al. Introduction of a novel GH auto-injector for once-weekly administration of TransCon hGH. Pediatric Endocrine Nurses Society 2021 National Conference; 2020; Virtual.","DOI":"10.1016\/j.pedn.2020.02.028"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1210\/jc.2015-1002","volume":"100","author":"Raman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000520812","volume":"94","author":"Allen","year":"2021","journal-title":"Horm Res Paediatr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2147\/JBM.S84597","volume":"7","author":"Djambas Khayat","year":"2016","journal-title":"J Blood Med"},{"key":"ref44","first-page":"313","volume":"4","author":"Jose","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1182\/blood-2019-128083","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/DMSO.S99732","volume":"9","author":"Qiao","year":"2016","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"150","DOI":"10.17458\/per.vol16.2018.mr.monitoringrhghsafety","volume":"16","author":"Miller","year":"2018","journal-title":"Pediatr Endocrinol Rev"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S2213-8587(20)30163-7","volume":"8","author":"Savendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000435856","volume":"84","author":"Swerdlow","year":"2015","journal-title":"Horm Res Paediatr"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1210\/jc.2016-2046","volume":"102","author":"Swerdlow","year":"2017","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=81804","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=81804","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T09:30:14Z","timestamp":1656495014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/spotlight-on-lonapegsomatropin-once-weekly-injection-and-its-potential-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":50,"URL":"https:\/\/doi.org\/10.2147\/dddt.s336285","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}